GOTHENBURG,Sweden,Sept. 17,2024-- The Board of Directors of SKF has decided to initiate a separation of its Automotive business with the objective of a separate listing onNasdaq Stockholm through a Le
SINGAPORE,Sept. 17,2024-- The Asia Pacific Enterprise Awards (APEA) 2024 proudly celebrated Taiwan\'s leading business leaders and enterprises driving the future of inclusive entrepreneurship. In an e
New ECW Results Report highlights significant learning outcomes achieved for children and adolescents in crisis settings and calls for urgent additional donor support to meet the rapidly escalating ne
MANILA,Philippines,Sept. 18,2024-- The annual ASEAN Innovation Business Platform (AIBP) Enterprise Innovation Awards received 113 submissions from public and private organisations throughout Southeast
92% of Asia Pacific and Japan midmarket businesses say adopting generative AI is a top business priority
In the realm of innovative printing solutions, CYCJET stands out as a leading brand that continuously pushes the boundaries of what's possible.
At the beginning of this year, the US Securities and Exchange Commission approved the Bitcoin spot ETF for the first time and authorized a total of 11 listed trading products. Subsequently, 9 Ethereum ETFs were approved for listing and trading in July. Since the approval of the Bitcoin spot ETF, a large amount of investment funds have continued to pour in, further driving up the price of Bitcoin. Large institutions such as BlackRock, Grayscale, and Fidelity have accumulated $58 billion worth of Ethereum smart contract ETFs.
The "Experience Macao Limited Edition" International Promotional Campaign, launched by the Macao Government Tourism Office (MGTO), is making waves worldwide. The campaign has introduced a simple and easy-to-play quiz game, offering participants the chance to win 100 “Experience Macao Limited Edition prizes”, showcasing Macao's rich cultural heritage and vibrant attractions.
SUZHOU,China,Sept. 16,2024--Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presente